Specifications TableSubjectMedicine and DentistrySpecific subject areaPathology and Medical TechnologyType of dataTables\
Figures\
Supplemental filesHow data were acquiredRetrospective chart and data review from laboratory analysis performed at an academic medical center central clinical laboratory were obtained via tools within the electronic medical record.Data formatRaw and AnalyzedParameters for data were collectionRetrospective data on all HIV screening and confirmatory tests was obtained from the electronic medical record (Epic, Inc.) covering the time period from January 1, 2014 through May 24, 2017. Detailed chart review was performed for all cases with positive HIV screening results except for testing for blood borne pathogen (BBP) exposures that were restricted from chart review. The project had approval from the University of Iowa Institutional Review Board.Description of data collectionThere were a total of 23,331 HIV screening tests performed on 19,177 (Architect 9,302, Bioplex 9,875) unique patients for clinical purposes during the retrospective analysis period. The study was a retrospective study approved by the University of Iowa Institutional Review Board (protocol \# 201705802). The data collection also contains confirmatory HIV testing for positive screens.Data source locationIowa City, Iowa, United States of AmericaData accessibilityRaw data are available in this article as 2 Supplementary files. Five tables and two figures are included within the paper.

Value of the Data {#sec0001a}
=================

•The data provided are of value as HIV screening is widely performed in clinical, research, and public health settings.•Clinicians, other researchers, or personnel in clinical laboratories might find this data useful as a reference for comparison.•Our data set would serve as a starting point for researchers interested in future investigations investigating HIV screening false positives.•The data are of value as there is very limited published data involving the relationship of signal/cutoff ratio and confirmation in 5^th^ generation HIV screening tests.•The data provide information for 23,331 HIV screening tests in 19,177 unique patients.

1. Data {#sec0001}
=======

In this retrospective analysis study, we compiled detailed data on 23,331 samples originating from 19,177 unique patients that had HIV screening testing performed at an academic medical center central clinical laboratory. There is a growing literature on the association of HIV screening assay signal-to-cutoff (S/CO) value with likelihood of subsequent confirmation by confirmatory testing such as Western blot, antibody differentiation assays, and HIV RNA PCR assay [@bib0001], [@bib0002], [@bib0003], [@bib0004], [@bib0005], [@bib0006]. There were a total of 2,657 (Architect 2,002; 655 Bioplex) tests ordered as part of workup for BBP exposure to employees or students. For the purposes of the present study, a true (confirmed) positive was determined by a positive result by Western blot, Bio-Rad Multispot, or Bio-Rad Geenius (note only Multispot and Geenius assays can differentiate between HIV-1 and HIV-2 Ab) and/or HIV RNA PCR. A non-true positive screen was defined as a reactive HIV screen without subsequent confirmation/diagnosis of HIV infection. To best ascertain HIV status, we performed extensive chart review in addition to analyzing the results of HIV discriminatory and RNA PCR testing.

[Table 1](#tbl0001){ref-type="table"} shows demographics of the population being tested, both overall and for those with positive screening tests. [Table 2](#tbl0002){ref-type="table"} shows overall performance characteristics of the two HIV screening assays. [Table 3](#tbl0003){ref-type="table"} shows the S/CO quantitative values associated with reactive HIV screens. [Table 4](#tbl0004){ref-type="table"} summarizes the discrete components for reactive HIV screens for the 5th generation Bioplex assay. [Table 5](#tbl0005){ref-type="table"} summarizes the performance of the two HIV screening tests using selected S/CO ratio thresholds. [Fig. 1](#fig0001){ref-type="fig"} displays the distribution of S/CO ratios for positive HIV screens for the Abbott Architect and Bioplex assays, indicating no overlap between the S/CO ratios for non-true positives and confirmed positives for either assay. [Fig. 2](#fig0002){ref-type="fig"} is a histogram plot of the S/CO ratios of HIV screens that were negative (\< 1.0) on the Bioplex assays. The raw data for the study are included in Supplementary file 1 (Abbott Architect assay) and Supplementary file 2 (Bioplex assay).•Supplementary file 1: Data for 11,987 HIV screening tests on 9,302 unique patients using the Abbott Architect 4^th^ generation HIV assay. All laboratory data involve analysis on serum/plasma. Specific data fields include: unique patient identification number (deidentified), location/unit at time of testing (emergency department, inpatient, or outpatient), age in years, birth sex, HIV screening result, S/CO ratio (if available), confirmation method (Multi-spot or Western blot, if performed), confirmation result (if available), and HIV-1 PCR results (if available).•Supplementary file 2: Data for 11,344 HIV screening tests on 9,875 unique patients using the Bioplex 5^th^ generation HIV assay. All laboratory data involve analysis on serum/plasma. Specific data fields include: unique patient identification number (deidentified), location/unit at time of testing (emergency department, inpatient, or outpatient), age in years, birth sex, HIV screening result, S/CO ratio (if available), confirmation method (Multi-spot or Geenius blot, if performed), confirmation result (if available), and HIV-1 PCR results (if available).Table 1Demographics of HIV testingTable 1ArchitectBioplexHIV screeningn = 11987n = 11344**Location**Inpatient1517 (12.7%)1259 (11.1%)Outpatient10218 (85.2%)9790 (86.3%)Emergency department252 (2.1%)295 (2.6%)**Highest ordering specialty**Obstetrics-gynecology2567 (21.4%)3555 (31.3%)Family medicine1352 (11.3%)1372 (12.1%)Transplant services867 (7.2%)772 (6.8%)Internal medicine539 (4.5%)558 (4.9%)**Confirmed positive screen**Mean age (yrs)46 ± 1141 ± 13Median age (yrs)4640Male: female3:13:1**Non-true positive screen (initial screen positive, not confirmed)**Mean age (yrs)40 ± 1539 ± 14Median age (yrs)3334Male: female0.60.8:1Table 2Performance of Architect and Bioplex HIV Ag/Ab assaysTable 2ArchitectBioplexTotal**HIV screening**n = 11987n = 11344n = 23331Reactive screens5258110Nonreactive screens119351128623221**HIV confirmation**Confirmed positives222749 Positive Western Blot7N/A7 HIV-1 by Multispot141832 HIV-2 by Multispot[a](#tb2fn1){ref-type="table-fn"}101 HIV-1 by GeeniusN/A99Non-true positives (confirmation negative)263157Confirmatory test cancelled[b](#tb2fn2){ref-type="table-fn"}404†**Specificity**(95% CI)99.8% (99.7 - 99.9%)99.7% (99.6 - 99.8%)99.8% (99.7 - 99.8)%**Positive Predictive Value**(95% CI)45.8% (36.6 -55.4%)46.6% (38 -55.3%)46.2% (39.9 -52.7%)[^1][^2]Table 3S/CO Ratio Quantitative Values for Reactive ScreensTable 3Architect HIV Ag/Ab Combo Assay[a](#tb3fn1){ref-type="table-fn"}S/CO ratioNegative confirmationPositive confirmationn = 11n = 12Median2826Minimum1199Maximum391094Bioplex HIV Ag/Ab Combo Assay[b](#tb3fn2){ref-type="table-fn"}S/CO ratioNegative confirmationPositive confirmationn = 31n = 27Median3\>200Minimum1131Maximum45\>200 (n = 19)[^3][^4]Table 4Discrete component for reactive Bioplex screensTable 4Reactive component (S/CO ratio ≥ 1)HIV-1 AbHIV-2 AbHIV-1 p24 AgHIV-1 Ab, HIV-2 Ab[a](#tb4fn1){ref-type="table-fn"}HIV-2 Ab, HIV-1 p24 Ag[a](#tb4fn1){ref-type="table-fn"}HIV-1 Ab, HIV-2 Ab, HIV-1 p24 Ag[a](#tb4fn1){ref-type="table-fn"}Confirmed positive screens (n = 27)2700000Non-true positive screens (n = 31)2210215[^5]Table 5Performance with Selected S/CO Ratio ThresholdsTable 5Abbott Architect HIV Ag/Ab Combo AssayS/CO ratio[a](#tb5fn1){ref-type="table-fn"}PPV (%)Sensitivity (%)\>200100%100%\>150100%100%\>100100%100%Bio-Rad Bioplex HIV Ag/Ab Combo AssayS/CO ratioPPV (%)Sensitivity (%)\>200100%70.4%\>150100%88.9%\>100100%100%[^6]Fig. 1Distribution of S/CO ratios for Confirmed Positives and Non-True Positive Results. Note: 19 Bioplex specimens had S/CO ratios that exceeded 200 (plotted together at 200).Fig 1Fig. 2Distribution of S/CO ratios of negative Bioplex screens.Fig 2

2. Experimental Design, Materials, and Methods {#sec0002}
==============================================

This was a retrospective study approved by the University of Iowa Institutional Review Board (protocol \# 201705802). During the retrospective analysis period, initial HIV testing was performed using the Abbott Architect HIV Ag/Ab immunoassay (Abbott Laboratories, Architect Park, IL) January 1, 2014 to November 22, 2015, which then transitioned to the Bio-Rad Bioplex 2200 HIV Ag-Ab Assay (Bioplex Laboratories, Hercules, CA) November 23, 2015 to May 24, 2017. The Abbott Diagnostics Architect HIV Ag/Ab Combo Assay is a widely used chemiluminescent 4^th^ generation assay that simultaneously detects HIV-1 p24 Ag, HIV-1 gp41 Ab, and HIV-2 gp36 Ab and outputs a single signal-to-cutoff (S/CO) ratio that translates into a reactive/nonreactive qualitative result [@bib0005],[@bib0007], [@bib0008], [@bib0009]. An S/CO ratio of 1.0 or greater on the Architect assay is considered positive, with repeat testing to verify the result. The Bio-Rad Bioplex 2200 HIV Ag-Ab Assay is an automated, multiplex flow 5^th^ generation HIV immunoassay that provides discrete S/CO ratio results from detection of HIV-1 p24 Ag, HIV-1 Ab (groups M and O), and HIV-2 Ab, with similar overall sensitivity and specificity to other combination HIV Ag-Ab assays [@bib0010],[@bib0011]. An S/CO ratio of 1 or greater on any of the three components of the Bioplex assay is interpreted as a positive screen, with repeat testing for all Bioplex positive screens before proceeding to confirmatory testing [@bib0012].

Beginning March 2015, quantitative S/CO ratios were captured in the laboratory information system and were thus available for 23 of 52 reactive Architect screens and all Bioplex HIV screens. The S/CO ratio for the Bioplex assay was determined by the highest S/CO ratio of the three components (HIV-1 p24 Ag, HIV-1 Ab groups M and O, and HIV-2 Ab). Reflex discriminatory or antibody differentiation testing for reactive screens (S/CO ratios of 1.0 or greater) was performed using Western blot for HIV-1 referred to a commercial reference laboratory (ARUP Laboratories, Salt Lake City, UT) January 2014 to October 2014, Bio-Rad Multispot HIV-1/HIV-2 Antibody Differentiation (Bio-Rad Laboratories, Redmond, WA) October 2014 to December 2016, or Bio-Rad Geenius HIV-1/HIV-2 Antibody Differentiation (Bio-Rad Laboratories, Redmond, WA) December 2016 to May 2017. These discriminatory tests, if positive, can confirm HIV infection. Medical record review was performed for all cases with S/CO ratio ≥ 1, except for cases in which HIV testing was ordered on a source patient, exposed employee, or student as part of a blood-borne pathogen (BBP) exposure workup (e.g., needlestick or scalpel injury). Due to restricted access, data for HIV screening in BBP exposures was limited to HIV screening and confirmation laboratory results.

Appendix. Supplementary materials {#sec0004}
=================================
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[^1]: HIV-2 RNA was detected (but below the limited of quantification, \<10 copies/mL) by subsequent HIV-2 PCR performed at the University of Washington (Seattle, WA) and New York State Department of Health Wadsworth Center (Albany, NY.) This sample was also screen positive on the Bioplex assay when tested as part of validation studies.

[^2]: Confirmatory testing was cancelled in 4 cases for the Abbott Architect testing due to previously established HIV-1 diagnosis.

[^3]: S/CO ratios were only available for 23 of 52 Architect positive screens. A single patient with a reactive Architect result had confirmed HIV-2 infection. Initial HIV testing was performed in this patient as part of routine screening for solid organ transplant evaluation. The quantitative S/CO ratio on the Architect assay was 237.48. The sample was later tested as part of validation studies for the Bioplex assay and had an S/CO ratio of \> 200 for HIV-2 Ab (\<1 for the two HIV-1 discrete components). HIV-2 antibodies were detected by Multispot confirmation. HIV-2 RNA was detected although below the assay\'s limit of quantitation (\<10 copies/mL) by real-time PCR (University of Washington Medical Center, Seattle, WA). HIV-2 RNA remained detectable at 8 and 9 months by real-time PCR but was no longer detected at 19 months from initial screening.

[^4]: S/CO ratios had maximum upper limit of 200 for the Bioplex. All values above this were simply reported as \> 200.

[^5]: These Bioplex patterns combined cross-reactivity for HIV-1 Ab and HIV-2 Ab and are designated in the assay package insert as "undifferentiated HIV", a result pattern uncommonly associated with actual HIV infection.

[^6]: S/CO quantitative values were available for 23 of 52 reactive Architect screens and 58 of 58 reactive Bioplex screens.
